However, a precise history is difficult because the modern concept of being transgender, and gender in general, did not develop until the mid-1900s. Historical understandings are thus inherently filtered through modern principles, and were largely viewed through a medical lens until the late 1900s.Ancient Greek Hippocrates (interpreting the writing of Herodotus) discusses transgender individuals briefly. He describes the "disease of the Scythians" (regarding the Enaree), which he attributes to impotency due to riding on a horse without stirrups. Hippocrates reference was well discussed by medical writings of the 1500s–1700s. Pierre Petit writing in 1596 viewed the "Scythian disease" as natural variation, but by the 1700s writers viewed it as a "melancholy", or "hysterical" psychiatric disease. By the early 1800s, being transgender separate from Hippocrates idea of it was claimed to be widely known, but remained poorly documented. Both MtF and FtM individuals were cited in European insane asylums of the early 1800s. The most complete account of the time came from the life of the Chevalier dÉon (1728–1810). As cross-dressing became more widespread in the late 1800s, discussion of transgender people increased greatly and writers attempted to explain the origins of being transgender. Much study came out of Germany, and was exported to other Western audiences. Cross-dressing was seen in a pragmatic light until the late 1800s; it had previously served a satirical or disguising purpose.
Society and culture
Generic names
Testosterone cypionate is the generic name of the drug and its USP. The drug does not have an INN, USAN, or BAN. It has also been referred to as testosterone cipionate, as well as testosterone cyclopentylpropionate or testosterone cyclopentanepropionate. Brand names
Testosterone cypionate is or has been marketed under a variety of brand names, including:
Andro Cyp
Andronaq LA
Andronate
Dep Andro
Dep Test
Deposteron
Depostomead
Depotest
Depo-Testosterone
Depovirin
Durandro
Duratest
Jectatest
Malogen CYP
Pertestis
Testa-C
Testadiate Depo
Testex Elmu Prolongatum
Testoject LA
Virilon

Availability
Testosterone cypionate is marketed in the United States. It is not widely available outside of the United States, though it has been marketed in Canada, Australia, Spain, Brazil, and South Africa. Legal status
Testosterone cypionate, along with other AAS, is a schedule III controlled substance in the United States under the Controlled Substances Act and a schedule IV controlled substance in Canada under the Controlled Drugs and Substances Act. == References ==